| Pharmaceutical active ingredients: |
| Neostigmine BromideNeostigmine Methylsulfate |
| Available forms, composition and doses of Neostigmine: |
| Injectable; Injection; Neostigmine Methylsulfate 0.5 mg / mlInjectable; Injection; Neostigmine Methylsulfate 2.5 mg / mlTablets; Oral; Neostigmine Bromide 15 mg |
| Neostigmine medical category: |
| Human:Parasympathomemetic (cholinergic) agents |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| N07AA01 - NeostigmineS01EB06 - Neostigmine |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| AstraZeneca |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Naropina | Ropivacaine Hydrochloride Monohydrate | AstraZeneca |
| Nasapert | Brompheniramine Maleate; Phenylpropanolamine Hydrochloride | AstraZeneca; Continental Pharma |
| Nasin | Oxymetazoline Hydrochloride | AstraZeneca; Leti Laboratorios |
| Neksium | Esomeprazole | AstraZeneca |
| Neo Atromid | Clofibrate | AstraZeneca |
| Nesacain | Chloroprocaine Hydrochloride | AstraZeneca |
| Nesacaine | Chloroprocaine Hydrochloride | AstraZeneca; APP Pharmaceuticals |
| Nesacaine CE | Chloroprocaine Hydrochloride | AstraZeneca |
| Nesacaine-MPF | Chloroprocaine Hydrochloride | AstraZeneca; APP Pharmaceuticals |
| Nesacain-MPF | Chloroprocaine Hydrochloride | AstraZeneca |